Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | CDK4 | P11802 | 2/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471815 | 0.93 | ALDH1A1 (0.39) | GSK3BCDK2MGLLCDK4MEN1 | |
| SCHEMBL4468006 | 0.81 | TDP1 (0.40) | GSK3BCDK2MEN1ALDH1A1KMT2A | |
| SCHEMBL4478445 | 0.78 | DYRK1A (0.43) | MGLLCDK4ALDH1A1KMT2APTGS2 | |
| SCHEMBL4467383 | 0.76 | TDP1 (0.38) | GSK3BCDK2MGLLMEN1ALDH1A1 | |
| SCHEMBL4467390 | 0.76 | TDP1 (0.38) | GSK3BCDK2MGLLMEN1ALDH1A1 | |
| SCHEMBL4471819 | 0.73 | PTGS2 (0.52) | GSK3BCDK2MEN1KMT2AKDR | |
| SCHEMBL4479972 | 0.70 | KDR (0.45) | CDK4MEN1ALDH1A1KMT2AKDR | |
| SCHEMBL4478240 | 0.70 | PTGS2 (0.56) | GSK3BKDRPTGS2 | |
| SCHEMBL4480066 | 0.70 | GSK3B (0.44) | GSK3BMEN1ALDH1A1KMT2AKDR | |
| SCHEMBL20669578 | 0.69 | DYRK1A (0.43) | MGLLCDK4MEN1KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885CDK2 91/4885MGLL 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.